Skip to main content

Table 3 Major milestones in the development of PM adoption in Singapore

From: Current landscape of personalized medicine adoption and implementation in Southeast Asia

Year

Organisation/ Initiative

Funder/Collaboration

Aim

2000

GISi

A*STAR

To use genomic sciences to achieve improvements in human health and public prosperity

2013

POLARIS

GIS, SingHealth

To deliver better patient outcomes through research within SingHealth institutionsj

2014

SAPhIRE

BMRC and the HSA, GIS, and the Translational Laboratory for Genetic Medicine

To develop an active surveillance network for ADR monitoring and discovery of genomic biomarkers that are predictive of specific ADRs

2015

PRISM

SingHealth and Duke-NUS Medical School

To drive, promote and standardize the use of PM and Precision Health for improving patient care, focusing on diseases relevant to Asian populations

  1. Notes
  2. i National flagship program for the genomic sciences
  3. j This includes Singapore General Hospital, National Cancer Centre Singapore, Singapore National Eye Centre, and NUS Health System
  4. Abbreviations
  5. A*STAR Agency for Science and Technology Research, ADR adverse drug reaction, BMRC Biomedical Research Council, GIS Genome Institute of Singapore, HSA Health Sciences Authority, NUS National University of Singapore, POLARIS Personalised OMIC Lattice for Advanced Research and Improving Stratification, PRISM SingHealth Duke-National University Singapore Institute of Precision Medicine, SAPhIRE Surveillance and Pharmacogenomics Initiative for Adverse Drug Reactions
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us